Demonstrating its commitment to the neuroscience space, Takeda Pharmaceutical has signed a broad, two-component deal with Wave Life Sciences to discover, develop and commercialise rationally designed nucleic acid therapies for genetically defined neurological diseases.The Japanese company has bought options to co-develop and co-commercialise Wave’s pipeline programmes in Huntington’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and spinocerebellar ataxia type 3. Takeda also receives the right to license multiple preclinical programmes targeting CNS disorders, including Alzheimer’s disease and Parkinson’s disease.